百亿ADC抗癌药赛道迎新玩家,药企期待多元化支付提高可及性

澎湃新闻
May 15

国内ADC(抗体偶联)领域又迎来重磅选手!  近日,葛兰素史克(GSK)宣布,其注射用玛贝兰妥单抗(商品名:倍乐锐)与硼替佐米和地塞米松(BVd)联合用于治疗既往接受过至少一线治疗的多发性骨髓瘤成年患者。该药是目前唯一一个获批用于治疗多发性骨髓瘤的抗B细胞成熟抗原(BCMA)ADC药物,可在多种治疗场景中以30分钟的门诊输注方式满足患者多样化的治疗需求。  ADC是一种靶向癌症疗法,兼具单克隆抗体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10